PPARγ: A turning point for irritable bowel syndrome treatment

Life Sciences
Nazanin Momeni RoudsariAmir Hossein Abdolghaffari

Abstract

Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal (GI) disorder with negative impacts on quality of life of patients. Although the etiology of the disease is still unclear, there are a set of mechanisms and factors involved in IBS pathogenesis. Visceral hypersensitivity, impaired gut barrier, along with minor inflammation and oxidative stress are the most important triggers for IBS induction. Activation of peroxisome proliferator activated receptor-γ (PPAR-γ) has been shown to improve gut barrier, downregulate pro-inflammatory cytokines, reduce free radical production through antioxidative mechanisms, and exert anti-nociceptive effects against somatic pain. An electronic search in PubMed, Google Scholar, Scopus, and Cochrane library was performed and relevant clinical, in vivo and in vitro articles published between 2004 and June 2020 were collected. Search terms included "Irritable Bowel Syndrome" OR "IBS" OR "visceral hypersensitivity" OR "motility dysfunction" AND "peroxisome proliferator activated receptors" OR "PPAR". Herein, the efficacy of PPARγ signaling as a potential target for IBS treatment is reviewed.

Citations

Apr 4, 2021·International Journal of Molecular Sciences·Guglielmina ChimientiFrancesco Russo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

The Journal of the Association of Physicians of India
H G Desai
Nihon rinsho. Japanese journal of clinical medicine
Tomomi Hattori, Shin Fukudo
Advances in Medical Sciences
Joanna OświęcimskaJarosław Kwiecień
JAMA : the Journal of the American Medical Association
William D CheyShanti Eswaran
© 2021 Meta ULC. All rights reserved